Status:
COMPLETED
The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
Retinoschisis
Eligibility:
MALE
12+ years
Phase:
PHASE2
Brief Summary
X-linked retinoschisis (XLRS) is a rare hereditary eye disease that causes irreversible vision loss in boys and young men. This disease occurs in 1 in 10,000-30,000. This inherited condition is caused...
Eligibility Criteria
Inclusion
- Patients with XLRS with cystoid fluid collections involving the fovea confirmed on SD- OCT
- are willing to undergo ophthalmic examinations at seven separate occasions;
- have no visual dysfunction that is also significantly associated with other ocular diseases besides XLRS (e.g., glaucoma, perforating trauma);
- have no known (non-)ocular disease/disorder which may influence the results of the measurements.
Exclusion
- Severe hepatic impairment
- Severe renal insufficiency
- Sodium and Potassium Depletion
- Addison's disease
- Hyperchloremic Acidosis
- Cor pulmonale
- Chronic non-congestive angle-closure glaucoma
- Usage of acetazolamide
- Known allergy or intolerance for ocular anesthetic eye drops oxybuprocaine 0.4% or mydriatics tropicamide 0.5% and/or phenylephrine 5%;
Key Trial Info
Start Date :
January 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2024
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT06114537
Start Date
January 20 2023
End Date
September 13 2024
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam University Medical Centers
Amsterdam, North Holland, Netherlands, 1105AZ